Background: Patients with triple negative breast cancer (TNBC) comprise a heterogeneous and poor-prognosis subgroup. Biomarkers for targeted therapy development remains a challenge. Progression of TNBC is associated with extracellular matrix (ECM) remodeling and reactivation of the paracrine Hedgehog (Hh) pathway, highlighting the relevance of tumor micronvironment (TME) in tumorigenesis. We investigated whether TME biomarkers could determine clinical response in TNBC patients treated with the Hh pathway inhibitor sonidegib in combination with docetaxel. Methods: Patients enrolled in GEICAM/2012-12 (EDALINE) trial were included (n ¼ 12). To evaluate Hh pathway activation, the expression of SHH and GLI1 was centrally examined by immunohistochemistry in pre-treatment primary tumors. A Hh Pathway Activation Signature (HPAS) was defined when SHH expression in epithelium and GLI1 in stroma were high (> median). Biomarkers involved in formation and degradation of ECM (C1M, C3M, C4M, C6M, pro-C3, pro-C6, CRPM, Loxl-2 and VCANM) were evaluated by ELISA (Protein Fingerprint TM ) in sequential plasma samples. ECM signature (ECMS) was defined when C4M and VCANM were high at baseline (> median). Results: Related to Hh pathway activation, only 10 tumors had IHC results. Three patients had high HPAS, 2 of them experienced a clinical benefit, 1 complete response (CR) and 1 stable disease (SD) lasting 7.3 and 5.5 months, respectively. All patients with low HPAS expression progressed. An additional patient had clinical benefit but the status of Hh pathway activation was unknown. For ECM biomarkers, a maintained reduction was observed in the expression along treatment (C2D1-0.5h, C2D2-25h and C4D1) vs baseline for pro-C3 (12.8, 10.2 and 9.4 vs 16.6, p ¼ 0.05, p ¼ 0.03, p ¼ 0.25, respectively), and pro-C6 (9.2, 7.5 and 8 vs 9.95, p ¼ 0.13, p < 0.01, p ¼ 0.03, respectively). Interestingly, patients with high ECMS had better Progression Free Survival (p ¼ 0.02). Moreover, 4 patients out of 12 had high ECMS, 3 of them experienced a clinical response, 1 CR and 2 SD. All patients with low ECMS progressed. Conclusions: Hh pathway activation and ECM remodeling might be associated with improved benefit to sonidegib in combination with docetaxel in TNBC metastatic patients. Clinical trial identification: NCT02027376. Legal entity responsible for the study: GEICAM Spanish Breast Group. Background: Current cancer treatment paradigms are based on features of the primary tumour and extent of disease. Carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer in the absence of an identifiable primary tumour. As such it is difficult to determine the optimal treatment strategy and 5-year survival rates are less than 20%. This poor survival rate is due to both the unclassifiable metastatic malignancy and the use of empirical broad-spectrum chemotherapy. A shift towards personalising cancer management based on mutation profiling has been explored in many cancer types including CUP. Small studies have reported durable treatment responses in CUP patients receiving targeted therapies, specifically when EGFR and KIT variants are detected. The present study has explored whether biologically important oncogenic driver mutations and potentially actionable targets are present in CUP that have potential to better inform treatment decisions. Methods: CUP cases (n ¼ 32) diagnosed on histopathology criteria were selected for study. Sections were cut from paraffin blocks of formalin-fixed tissue and DNA isolated. Extracted DNA was amplified with the Ion AmpliSeq Cancer Hotspot panel and Oncomine Focus panel for the identification of biologically relevant and actionable mutations, respectively. Amplified DNA was sequenced using the Ion Torrent platform and data was processed using a stringent variant filtration pipeline. Results: Biologically relevant or therapeutically druggable variants were detected in 88% (n ¼ 28) of cases. The most common variants were in TP53 (47%), KRAS (19%), MYC (6%), BRAF (6%) and CDKN2A (6%). There were potentially actionable targets in 14/32 (44%) cases, with the most common druggable variants being in the KRAS gene (exon 1) (6 cases) and MYC gene amplifications (2 cases). Conclusions: This retrospective study successfully identified biologically relevant variants in 88% of CUP cases. 50% of these variants were potentially actionable with drugs currently approved for use in known primary cancer types or undergoing clinical trials. This would give a novel treatment option to patients with a currently incurable disease with poor survival. The data therefore supports the use of NGS at diagnosis to give biological insight into the drivers leading to the malignancy, and to allow consideration of novel targeted treatment options. Legal entity responsible for the study: Translational Cancer Pathology Laboratory Funding: PathWest Disclosure: All authors have declared no conflicts of interest.
